Business Context and Reporting Period
This Form 8-K was filed by CytoSorbents Corporation on July 22, 2019. The report details executive compensation adjustments approved by the Compensation Committee of the Board of Directors.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation.
| Executive Officer | Position | Fiscal 2019 Base Salary | Stock Options Granted | RSUs Granted |
|---|---|---|---|---|
| Phillip P. Chan, MD, PhD | CEO and President | $438,000 | 80,000 | 60,000 |
| Vincent J. Capponi | COO | $363,540 | 68,000 | 54,100 |
| Kathleen P. Bloch | CFO | $323,025 | 60,000 | 43,000 |
| Eric R. Mortensen | CMO | $355,950 | 48,700 | 12,200 |
Option Terms: Strike price of $7.33 (closing price on grant date); 10-year term. Vesting occurs over three years (25% annually for options; 33% annually for RSUs).
Material Changes
- Base Salary Increases: Effective January 1, 2019, the CEO, COO, and CFO received approximately a 9.5% increase in annual base salary. The CMO received approximately a 5.0% increase.
- Equity Awards: New stock options and restricted stock units were granted on July 22, 2019, under the 2014 Long-Term Incentive Plan.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. The compensation adjustments were made in connection with annual performance reviews.
Investor Verification Checklist
- Verify the impact of the new equity grants on total shareholder dilution.
- Confirm the vesting schedules and service conditions for the granted options and RSUs.
- Review the 2014 Long-Term Incentive Plan to ensure the awards comply with plan limits.
- Assess the relationship between the salary increases and the company's current financial performance.